Dapagliflozin

Adults with type 2 diabetes experienced no difference in cardiovascular autonomic neuropathy measures or B-type natriuretic peptide levels after 12 weeks of dapagliflozin therapy vs. 12 weeks of glimepiride, according to trial data.

Efficacy of dapagliflozin (Farxiga, AstraZeneca) in patients with cardiometabolic risk factors hospitalized with COVID-19.

HF and type 2 diabetes are intertwined. Their shared pathophysiology can accelerate debilitating outcomes for patients that clinicians struggle to prevent and treat.

Heart failure and type 2 diabetes are exquisitely intertwined. Their shared pathophysiology can accelerate debilitating outcomes for patients that clinicians struggle to prevent and treat.

The SGLT2 inhibitor dapagliflozin did not significantly reduce risk for organ failure or death or improve recovery among adults hospitalized with COVID-19 vs. placebo, though data showed lower event numbers among treated patients.

Top-line data from the phase 3 DARE-19 trial show that the SGLT2 inhibitor dapagliflozin failed to prevent organ dysfunction and all-cause mortality among hospitalized patients with COVID-19 at risk for developing serious complications.

The American College of Cardiology announced its lineup of late-breaking clinical trials selected for presentation at its virtual 2021 Scientific Session.

Health care conferences around the world looked completely different in 2020 as the COVID-19 pandemic forced organizations to conduct virtual meetings.

Healio and Cardiology Today have aggregated the most-read HF news of 2020.

Healio and Cardiology Today have curated a list of the top news of 2020 in diabetes and the heart.